Immunovaccine to Host Investor Event on April 10, 2018 in New York City

World News: . []

HALIFAX, Nova Scotia, March 13, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, announced today that it will host an R&D Update and Investor Event for the investment community on Tuesday, April 10, 2018 in New York City.  

The event will feature an overview of Immunovaccine’s novel approach to targeted T cell therapy. Presentations by outside experts and Immunovaccine management will highlight the scientific background and key opinion leaders’ (KOL) perspectives on the company’s novel mechanism of action and its clinical applications and potential benefits. 

Details for the event are as follows:

The agenda will include:

If you are a member of the investment community and would like to attend, please send an email to to receive additional information.

A live broadcast of the event will be made available on the Investors section of the Immunovaccine website at . More information about how to access the webcast will be available closer to the event. 

Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops T cell activating cancer immunotherapies and infectious disease vaccines based on DepoVax™, the Company’s patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Company assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The Company is also exploring additional applications of DepoVax™, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at .

Patti Bank, Managing Director, Westwicke Partners O: (415) 513-1284 T: (415) 515-4572 E: 

More news and information about Immunovaccine Inc.

Published By:

Globe Newswire: 20:05 GMT Tuesday 13th March 2018

Published: .

Search for other references to "immunovaccine" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers